Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

October 01, 2006 (Vol. 26, No. 17)

Inflammation Research Leads to Targets

Safer and More Effective Drugs Are the Focus

  • Late last month, GlaxoSmithKline (GSK; www.gsk.com) and ChemoCentryx (www.chemocentryx.com) signed a multitarget strategic alliance, potentially worth 1.5 billion, to discover, develop, and market novel medicines targeting four chemokine and chemoattractant receptors for the treatment of a variety of inflammatory disorders. ChemoCentryx will be responsible for the discovery and ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.